Trial Profile
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary) ; Escitalopram (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 13 Jan 2022 This trial has been completed in Romania (End Date: 13 Sep 2011), according to European Clinical Trials Database record.
- 05 Apr 2012 Planned number of patients changed from 1200 to 1500 as reported by European Clinical Trials Database.
- 13 Mar 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.